UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

The regulation of BAI1 in astrocytes through the STAT3/EZH2 axis relieves neuronal apoptosis in rats with Alzheimer’s disease

Brain research, 2024-05, Vol.1839, p.149007-149007, Article 149007

2024

Link zum Volltext

Verfügbarkeit prüfen

Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer

International immunopharmacology, 2023-11, Vol.124, p.110918-110918, Article 110918

2023

Link zum Volltext

Verfügbarkeit prüfen

Cross-species analyses unravel the complexity of H3K27me3 and H4K20me3 in the context of neural stem progenitor cells

Neuroepigenetics, 2016-06, Vol.6, p.10-25

2016

Link zum Volltext

Verfügbarkeit prüfen

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

Biomedicine & pharmacotherapy, 2022-02, Vol.146, p.112532-112532, Article 112532

2022

Link zum Volltext

Verfügbarkeit prüfen

Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis

Journal of pineal research, 2016-09, Vol.61 (2), p.208-217

2016

Link zum Volltext

Verfügbarkeit prüfen

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

Cell reports (Cambridge), 2017-10, Vol.21 (3), p.628-640

2017

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer (Small 43/2023)

Small (Weinheim an der Bergstrasse, Germany), 2023-10, Vol.19 (43), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

Cell reports (Cambridge), 2018-12, Vol.25 (10), p.2808-2820.e4

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors

Biochemical pharmacology, 2023-09, Vol.215, p.115727-115727, Article 115727

2023

Link zum Volltext

Verfügbarkeit prüfen

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

BMC cancer, 2020-12, Vol.20 (1), p.1189-18, Article 1189

2020

Link zum Volltext

Verfügbarkeit prüfen

MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2–STAT3 signaling axis

Experimental cell research, 2018-05, Vol.366 (2), p.103-113

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

European journal of medicinal chemistry, 2023-12, Vol.261, p.115825-115825, Article 115825

2023

Link zum Volltext

Verfügbarkeit prüfen

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

Cancer cell, 2020-02, Vol.37 (2), p.157-167.e6

2020

Link zum Volltext

Verfügbarkeit prüfen

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes

Oncotarget, 2022, Vol.13 (1), p.677-683

2022

Link zum Volltext

Verfügbarkeit prüfen

The bone microenvironment increases phenotypic plasticity of ER + breast cancer cells

Developmental cell, 2021-04, Vol.56 (8), p.1100-1117.e9

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

Expert opinion on pharmacotherapy, 2023-08, Vol.24 (12), p.1395-1401

2023

Link zum Volltext

Verfügbarkeit prüfen

Enhancer of zeste homolog 2 (EZH2) inhibitors

Leukemia & lymphoma, 2018-07, Vol.59 (7), p.1574-1585

2018

Link zum Volltext

Verfügbarkeit prüfen

Loss of Ezh2 function remodels the DNA replication initiation landscape

Cell reports (Cambridge), 2023-04, Vol.42 (4), p.112280-112280, Article 112280

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

Frontiers in oncology, 2022-11, Vol.12, p.1081632-1081632

2022

Link zum Volltext

Verfügbarkeit prüfen

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis

Acta neuropathologica communications, 2022-04, Vol.10 (1), p.47-47, Article 47

2022

Link zum Volltext

Verfügbarkeit prüfen

GSK343 modulates macrophage M2 polarization through the EZH2/MST1/YAP1 signaling axis to mitigate neurological damage induced by hypercalcemia in CKD mice

Cellular signalling, 2024-04, Vol.116, p.111063-111063, Article 111063

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo

Biomaterials, 2018-02, Vol.155, p.112-123

2018

Link zum Volltext

Verfügbarkeit prüfen

EZH2 Promotes T Follicular Helper Cell Differentiation Through Enhancing STAT3 Phosphorylation in Patients With Primary Sjögren’s Syndrome

Frontiers in immunology, 2022-06, Vol.13, p.922871-922871

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

Pediatric blood & cancer, 2017-03, Vol.64 (3), p.np-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study

Clinical lymphoma, myeloma and leukemia, 2022-07, Vol.22 (7), p.504-512

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

ThemaBiochemistry & Molecular Biology

ThemaEzh2

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(179)
Life Sciences & Biomedicine
(163)
Humans
(96)
Oncology
(75)
Enhancer Of Zeste Homolog 2
(45)
Animals
(44)
Gene Expression
(43)
Cell Line, Tumor
(41)
Epigenetics
(41)
Enhancer Of Zeste Homolog 2 Protein - Genetics
(39)
Apoptosis
(37)
Ezh2 Inhibitor
(34)
Proteins
(34)
Tumors
(34)
Enhancer Of Zeste Homolog 2 Protein - Metabolism
(33)
Female
(33)
Cancer
(29)
Male
(29)
Mice
(29)
Mutation
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

The regulation of BAI1 in astrocytes through the STAT3/EZH2 axis relieves neuronal apoptosis in rats with Alzheimer’s disease

Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer

Cross-species analyses unravel the complexity of H3K27me3 and H4K20me3 in the context of neural stem progenitor cells

EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects

Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition

Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer (Small 43/2023)

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2–STAT3 signaling axis

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes

The bone microenvironment increases phenotypic plasticity of ER + breast cancer cells

Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

Enhancer of zeste homolog 2 (EZH2) inhibitors

Loss of Ezh2 function remodels the DNA replication initiation landscape

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis

GSK343 modulates macrophage M2 polarization through the EZH2/MST1/YAP1 signaling axis to mitigate neurological damage induced by hypercalcemia in CKD mice

Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo

EZH2 Promotes T Follicular Helper Cell Differentiation Through Enhancing STAT3 Phosphorylation in Patients With Primary Sjögren’s Syndrome

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study

Aktive Filter

Suchergebnisse filtern